2. UroToday Home
  3. Video Lectures

ASCO GU 2022

A Conversation on Changing Trends in Advanced RCC Treatment: An Analysis of Real-World Data - Neil Shah
Peer-Led Support Groups for Prostate Cancer Patient Care - Herbert Geller
Combination of Niraparib and Abiraterone Acetate Plus Prednisone Radiographic PFS as a First-Line Therapy in Patients with HRR Gene-Mutated mCRPC, MAGNITUDE - Cora Sternberg
The Caris Precision Oncology Alliance™ - Chadi Nabhan
The State of Bipolar Androgen Therapy in Prostate Cancer - Emmanuel Antonarakis
Identifying Unmet Needs in the Patient Journey in Prostate Cancer - Alicia Morgans
Beyond PSMA - New Targets in Prostate Cancer - Tanya Dorff
Treatment Considerations in Advanced Prostate Cancer - Bertrand Tombal
Atezolizumab in Advanced Penile Cancer With or Without Radiotherapy, PERICLES - Hielke Martijn De Vries
Overall Response Rate After Immune-Checkpoint Inhibitor Initiation and Post-ICI PFS in Patients With Advanced Urothelial Carcinoma - Dimitrios Makrakis
The First Neoadjuvant Trial Using Combination Immune Checkpoint Inhibitor and VEGF Inhibitor in Patients With Locally Advanced High-Risk RCC (NeoAvAx) – Axel Bex
Active Surveillance for Patients With Intermediate-Risk Prostate Cancer - Stacy Loeb
Microbiome Research in Bladder Cancer - Laura Bukavina
Final Analysis of the ATLANTIS Rucaparib Arm - Simon Crabb
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective - Scott Tagawa
Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher
The Role of Bladder-Sparing Trimodality Therapy - Sophia Kamran
Results from the Phase 3 SPOTLIGHT Trial of 18F-rhPSMA-7.3 in Recurrent Prostate Cancer - David Schuster
Sabizabulin in Phase 1b/2 Clinical Trials of Men With Metastatic Castration-Resistant Prostate Cancer Who Progressed on Androgen Receptor-Targeting Agents - Mark Markowski
Biological Pathways in Urothelial Carcinoma - Carissa Chu
Hereditary Cancer Risk Assessment For Prostate Cancer Patients - Neal Shore
Highlights of Urothelial and Prostate Cancer - 2022 GU ASCO Meeting - Scott Tagawa
The Impact of Imaging and Therapeutics Advances in Nonmetastatic Castration-Resistant Prostate Cancer - David Penson
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients with High-Grade Upper Tract Urothelial Carcinoma - Wesley Yip
Practice Changing Publications in Urothelial Carcinoma - Deborah Kaye
Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg
Symptoms Related to Bone Metastasis in Men Receiving Lutetium-177 PSMA-617 for Prostate Cancer - Brian Gonzalez
Treatment Strategies in Advanced Urothelial Carcinoma - Stephen Boorjian
A Real-World Study of PSA Response in Black and White Chemotherapy-Naive Prostate Cancer Patients Treated With Enzalutamide - Alicia Morgans
Darolutamide plus ADT in Metastatic Hormone-Sensitive Prostate Cancer - The ARASEC Trial - Neal Shore
Significant Improvement With Continuous Enzalutamide in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer – Axel Merseburger
Real-World Treatment Trends in Metastatic Castration-Sensitive Prostate Cancer - Pedro Barata
Molecular Biomarkers in Upper-Tract Urothelial Carcinoma - Janet Kukreja
The Future of Adjuvant and Neoadjuvant Therapy for Patients with Muscle-Invasive Bladder Cancer - Tracy Rose
Penile Squamous Cell Carcinoma Somatic Alterations - W. Michael Korn
TALAPRO-3 Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Neeraj Agarwal
The Effect of Durvalumab and Olaparib on Prolong Progression-Free Survival As First-Line Therapy in Platinum-Ineligible Patients With Unresectable Urothelial Carcinoma - The BAYOU Study – Jonathan Rosenberg
Treatment and Survival Differences in Patients With Urothelial Vs. Nonurothelial Bladder & Upper Tract Carcinomas - Jeanny Aragon-Ching
The Next Wave of Novel Radiopharmaceuticals - Shahneen Sandhu
Advanced Prostate Cancer Practice Informing Data Presented at ASCO GU 2022 - Oliver Sartor
Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng
ARANOTE - Darolutamide in Addition to ADT Vs. ADT in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) - Fred Saad
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) - Joaquin Mateo
KEYNOTE-564 30-Month Follow-Up of Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma - Toni Choueiri
The Efficacy and Safety of Olaparib + Abiraterone in the First-Line mCRPC Setting PROpel – Fred Saad
AI-Derived Digital Pathology-Based Biomarker To Predict the Benefit of ADT in Localized Prostate Cancer – Dan Spratt
The ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients - Alfredo Berruti
AI-derived Digital Pathology-Based Biomarkers in Localized Prostate Cancer - Felix Feng
The Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab in the Treatment of Cisplatin-Ineligible Patients in Advanced Urothelial Carcinoma (LEAP-011) - Yohann Loriot
DS8201-a-U105 Trial of Trastuzumab Deruxtecan With Nivolumab in Patients With Urothelial Carcinoma – Matt Galsky
Validation of Performance of the Decipher® Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski
First Results of MAGNITUDE – Niraparib with Abiraterone Acetate and Prednisone a First-Line Therapy in Metastatic Castration-Resistant Prostate Cancer – Kim Chi
Highlights In Urothelial Carcinoma at GU ASCO 2022 - Guru Sonpavde
Sacituzumab Govitecan in Combination with Pembrolizumab in Metastatic Urothelial Cancer - Petros Grivas
Next-Generation Sequencing: Discussing Results with Patients - Bishoy Faltas
Anticipated Data from Transformative Trials at ASCO GU 2022 - Oliver Sartor